News & Perspective

Oct 18, 2011

Oct 18, 2011

Anthrax countermeasures better than in 2001, but work remains

(CIDRAP News) – If someone tried to kill Americans with Bacillus anthracis spores today, the nation would have a better medical tool chest for treating the sick and those potentially exposed than it had 10 years ago, when the anthrax letter attacks killed five people, but anthrax defenses are still a work in progress.

Apr 26, 2010

Apr 26, 2010

H1N1 LESSONS LEARNED Vaccine production foiled, confirmed experts' predictions

Second in a series marking the 1-year anniversary of novel H1N1 pandemic influenza. The first, on the virus itself, appeared Apr 23.

Aug 21, 2009

Aug 21, 2009

First H1N1 vaccine trial data expected in mid-September

(CIDRAP News) – Federal health officials today said the first results of novel H1N1 vaccine trials—needed for determining the number and size of doses people will get—are expected in mid-September.

Two trials in adult and elderly volunteers started Aug 7 and are now almost fully enrolled, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), at a press teleconference.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Oct 25, 2007

Oct 25, 2007

THE PANDEMIC VACCINE PUZZLE Bibliography

Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Sort Results

 

Narrow results

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»